Benzinga | Oct 6, 2020 07:15AM EDT

Actinium Pharmaceuticals, Inc. Announces Clinical Trial Site Expansion In Multi-Center Phase 1/2 Actimab-A Venetoclax Combination Trial

NEW YORK, Oct. 6, 2020 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) ("Actinium" or the "Company") today announced that the University of Louisville and the Ochsner Clinic in New Orleans, Louisiana are now active trial sites in its Phase 1/2 Actimab-A venetoclax combination trial for patients with Relapsed or Refractory ("R/R") Acute Myeloid Leukemia ("AML") age 18 and above. These sites join UCLA Medical Center, where the trial is being led by Gary Schiller, MD, Professor, Hematology-Oncology and Director, Hematologic Malignancy/Stem Cell Transplant Program. Both sites participated in Actinium's Phase 2 trial with Actimab-A as a single agent that produced remission rates as high as 69% with minimal non-hematologic toxicities in patients newly diagnosed with AML. The Phase 2 trial results together with a synergistic mechanism of action with venetoclax demonstrated in pre-clinical studies are driving this combination trial with an initial focus on the high unmet needs of R/R patients including those who have relapsed or do not respond to treatment with venetoclax based regimens.